Towards Inhaled Phage Therapy in Western Europe
The emergence of multidrug-resistant bacteria constitutes a great challenge for modern medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and implementation of bacteriophage therapy by Western medicine might be one solution to the problem of increasing antibiotic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/11/3/295 |
| _version_ | 1818202266674397184 |
|---|---|
| author | Sandra-Maria Wienhold Jasmin Lienau Martin Witzenrath |
| author_facet | Sandra-Maria Wienhold Jasmin Lienau Martin Witzenrath |
| author_sort | Sandra-Maria Wienhold |
| collection | DOAJ |
| description | The emergence of multidrug-resistant bacteria constitutes a great challenge for modern medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and implementation of bacteriophage therapy by Western medicine might be one solution to the problem of increasing antibiotic failure. In some Eastern European countries phage therapy is used for treating infectious diseases. However, while the European Medicines Agency (EMA) advised that the development of bacteriophage-based therapies should be expedited due to its significant potential, EMA emphasized that phages cannot be recommended for approval before efficacy and safety have been proven by appropriately designed preclinical and clinical trials. More evidence-based data is required, particularly in the areas of pharmacokinetics, repeat applications, immunological reactions to the application of phages as well as the interactions and effects on bacterial biofilms and organ-specific environments. In this brief review we summarize advantages and disadvantages of phage therapy and discuss challenges to the establishment of phage therapy as approved treatment for multidrug-resistant bacteria. |
| first_indexed | 2024-12-12T03:06:43Z |
| format | Article |
| id | doaj.art-e7d50bdc15224eaeab502135e2ad3850 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-12-12T03:06:43Z |
| publishDate | 2019-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-e7d50bdc15224eaeab502135e2ad38502022-12-22T00:40:30ZengMDPI AGViruses1999-49152019-03-0111329510.3390/v11030295v11030295Towards Inhaled Phage Therapy in Western EuropeSandra-Maria Wienhold0Jasmin Lienau1Martin Witzenrath2Division of Pulmonary Inflammation, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, GermanyDivision of Pulmonary Inflammation, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, GermanyDivision of Pulmonary Inflammation, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, GermanyThe emergence of multidrug-resistant bacteria constitutes a great challenge for modern medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and implementation of bacteriophage therapy by Western medicine might be one solution to the problem of increasing antibiotic failure. In some Eastern European countries phage therapy is used for treating infectious diseases. However, while the European Medicines Agency (EMA) advised that the development of bacteriophage-based therapies should be expedited due to its significant potential, EMA emphasized that phages cannot be recommended for approval before efficacy and safety have been proven by appropriately designed preclinical and clinical trials. More evidence-based data is required, particularly in the areas of pharmacokinetics, repeat applications, immunological reactions to the application of phages as well as the interactions and effects on bacterial biofilms and organ-specific environments. In this brief review we summarize advantages and disadvantages of phage therapy and discuss challenges to the establishment of phage therapy as approved treatment for multidrug-resistant bacteria.https://www.mdpi.com/1999-4915/11/3/295bacteriophagephage therapymultidrug-resistant bacteriaantimicrobial resistance |
| spellingShingle | Sandra-Maria Wienhold Jasmin Lienau Martin Witzenrath Towards Inhaled Phage Therapy in Western Europe Viruses bacteriophage phage therapy multidrug-resistant bacteria antimicrobial resistance |
| title | Towards Inhaled Phage Therapy in Western Europe |
| title_full | Towards Inhaled Phage Therapy in Western Europe |
| title_fullStr | Towards Inhaled Phage Therapy in Western Europe |
| title_full_unstemmed | Towards Inhaled Phage Therapy in Western Europe |
| title_short | Towards Inhaled Phage Therapy in Western Europe |
| title_sort | towards inhaled phage therapy in western europe |
| topic | bacteriophage phage therapy multidrug-resistant bacteria antimicrobial resistance |
| url | https://www.mdpi.com/1999-4915/11/3/295 |
| work_keys_str_mv | AT sandramariawienhold towardsinhaledphagetherapyinwesterneurope AT jasminlienau towardsinhaledphagetherapyinwesterneurope AT martinwitzenrath towardsinhaledphagetherapyinwesterneurope |